Journal article

MAIT cells regulate NK cell-mediated tumor immunity

Emma Petley, Hui-Fern Koay, Melissa A Henderson, Kevin Sek, Kirsten L Todd, Simon P Keam, Junyun Lai, Imran G House, Jasmine Li, Magnus Zethoven, Amanda XY Chen, Amanda J Oliver, Jessica Michie, Andrew J Freeman, Lauren Giuffrida, Jack D Chan, Angela Pizzolla, Jeffrey YW Mak, Timothy R McCulloch, Fernando Souza-Fonseca-Guimaraes Show all

NATURE COMMUNICATIONS | NATURE PORTFOLIO | Published : 2021

Abstract

The function of MR1-restricted mucosal-associated invariant T (MAIT) cells in tumor immunity is unclear. Here we show that MAIT cell-deficient mice have enhanced NK cell-dependent control of metastatic B16F10 tumor growth relative to control mice. Analyses of this interplay in human tumor samples reveal that high expression of a MAIT cell gene signature negatively impacts the prognostic significance of NK cells. Paradoxically, pre-pulsing tumors with MAIT cell antigens, or activating MAIT cells in vivo, enhances anti-tumor immunity in B16F10 and E0771 mouse tumor models, including in the context of established metastasis. These effects are associated with enhanced NK cell responses and incre..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC)


Awarded by Cancer Council Victoria


Awarded by Priority-driven Collaborative Cancer Research Scheme


Awarded by National Breast Cancer Foundation Fellowship


Awarded by Victorian Cancer Agency Mid-Career Fellowship


Awarded by Victorian Cancer Agency Early Career Fellowship


Awarded by NHMRC Senior Research Fellowship


Awarded by NHMRC Senior Principal Research Fellowships


Awarded by NHMRC ECF Fellowship


Awarded by Australian Research Council


Funding Acknowledgements

The authors would like to acknowledge the assistance of the Animal Facility technicians at the Peter MacCallum Cancer Centre and Prof. Olivier Lantz for the provision of B6-MAITcast mice. This work was funded by Program Grants from the National Health and Medical Research Council (NHMRC; 1132373, 1113293, and 1140406) and a Cancer Council Victoria grant (APP1143517). F.S.F.G received a grant #1158085 awarded through the Priority-driven Collaborative Cancer Research Scheme and funded by Cure Cancer Australia with the assistance of Cancer Australia. P.A.B. was supported by National Breast Cancer Foundation Fellowship (ID# ECF-17-005, 2016-2020) and a Victorian Cancer Agency Mid-Career Fellowship (MCRF20011, 2021-current). I.G. House is supported by a Victorian Cancer Agency Early Career Fellowship (ECRF20017). P.K.D. is supported by an NHMRC Senior Research Fellowship (APP1136680). D.I.G. and F.P.F. are supported by NHMRC Senior Principal Research Fellowships (1117766, 1117017). H.-F.K. is supported by an NHMRC ECF Fellowship (1160333); D.I.G., H-F.K., J.Y.W.M., and D.P.F. are also supported by the Australian Research Council CE140100011.